Fig 2.

(A) Time to response after alemtuzumab. Patients receiving alemtuzumab had weekly blood counts for the first 3 months and every other week between 3 and 6 months. Response as a function of time was assessed using the Kaplan-Meier method. (B) Response duration in patients treated with alemtuzumab. Patients were monitored for evidence of relapse by routine blood counts as described in Patients and Methods. Relapse was defined as need for additional therapy including initiation of cyclosporine, growth factors, or androgens. Median duration of response has not yet been reached.